[Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
作者信息
Geissbühler F, Gaillard J M, Eisenring J J, Krassoievitch M, Yanniotis G, Tissot R
出版信息
Rev Eur Etud Clin Biol. 1972 Jan;17(1):38-44.
PMID:5041348
Abstract
摘要
相似文献
1
[Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
Rev Eur Etud Clin Biol. 1972 Jan;17(1):38-44.
2
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.帕金森病中的脑脊液单胺代谢产物与外周脱羧酶抑制剂
Neurology. 1970 Dec;20(12):Suppl:36-40.
3
Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.α-甲基多巴作为左旋多巴治疗帕金森病的辅助药物。
Trans Am Neurol Assoc. 1971;96:59-65.
4
[Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].[左旋多巴联合脱羧酶抑制剂治疗帕金森综合征。II]
Rev Neurol (Paris). 1970 Nov;123(5):297-319.
5
[Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Munch Med Wochenschr. 1973 Apr 20;115(16):711-3.
6
[Methyldopa and levodopa].
Zhonghua Yi Xue Za Zhi. 1974;7:439-41.
7
Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
Mayo Clin Proc. 1972 Jun;47(6):389-95.
8
L-Dopa, B 6 , and alpha-methyldopa hydrazine.左旋多巴、维生素B6和α-甲基多巴肼。
Confin Neurol. 1973;35(3):186-92.
9
[Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Rev Med Chil. 1973 Jun;101(6):452-5.
10
Modification of Parkinsonism--chronic treatment with L-dopa.帕金森病的改善——左旋多巴的长期治疗
N Engl J Med. 1969 Feb 13;280(7):337-45. doi: 10.1056/NEJM196902132800701.
引用本文的文献
1
Demethylation of L-3-methoxytyrosine in vivo.
Naunyn Schmiedebergs Arch Pharmacol. 1972;274(4):404-9. doi: 10.1007/BF00501277.
Zotero 插件